Amarin's Vascepa misses primary endpoint in Phase 3 colorectal cancer trial

Bitget2026/10/25 12:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amarin reported Phase 3 EMT2 results showing VAZKEPA/VASCEPA missed its primary goal of delaying cancer progression but improved overall survival.
The University of Leeds-sponsored trial evaluated adjunctive treatment in colorectal cancer patients undergoing surgery for liver metastases.
Results were presented at the European Society for Medical Oncology 2026 Congress in Madrid.
Treatment was well tolerated, with no excess adverse events or meaningful deterioration in quality of life versus placebo.
The findings support further evaluation of the cardiovascular drug’s potential use in cancer care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610250811PRIMZONEFULLFEED9852658) on October 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Amarin's Vascepa misses primary endpoint in Phase 3 colorectal cancer trial

You may also like

Crypto prices